ASB17

Across TCGA pan-cancer cohorts, ASB17 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated ASB17 data layer compared with 5 for mutation status.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher ASB17 RNA is associated with better overall survival. In most high-consensus cancer types, elevated ASB17 expression acts as an unfavorable survival marker, although some lineages such as KIRC and STAD show a favorable association.

KIRC, MESO, and BRCA are the cancer types where ASB17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.698	0.561	<.001	73	view →
MESO	DFS	Tertile	III,IV	0.143	0.384	.010	54	view →
BRCA	DFS	Tertile	All	0.814	0.910	.001	48	view →
THYM	OS	Tertile	All	0.585	0.930	.004	45	view →
UCS	DFS	Tertile	II,III,IV	0.124	0.467	<.001	36	view →
ACC	OS	Quartile	II,III,IV	0.539	0.823	.001	26	view →
CESC	DFS	Tertile	IV	0.053	0.529	<.001	18	view →
DLBC	OS	Tertile	IV	0.367	0.897	.018	18	view →
STAD	OS	Tertile	IV	0.682	0.258	.040	6	view →
KIRP	OS	Quartile	II,III,IV	1.000	0.571	.023	4	view →
SKCM	OS	Quartile	IV	0.456	0.880	.025	3	view →
LGG	DFS	Tertile	All	0.314	0.414	.044	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

ASB17–KIRC (OS)

Open the KIRC breakdown →